Please assess the completion status of the following clinical trial:

Trial Title: Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. OCD diagnosis~2. YBOCS score ≥ 16 (for patients with both obsessions and compulsions) or ≥ 10 (for patients with only obsessions or compulsions)~3. Previously signed informed consent to participate in this clinical trial~Exclusion Criteria:~1. Patients with clinical or neurological diseases that may be worsen by the medications included in treatment protocol~2. Current substance dependence or abuse~3. Current psychotic symptoms~4. Current suicide risk~5. Current pregnancy or intention to get pregnant before the end of the treatment protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Quetiapine (fluoxetine plus quetiapine) (Type: EXPERIMENTAL): fluoxetine up to 40mg once a day plus Quetiapine up to 200mg once a day, during 12 weeks
- Clomipramine (fluoxetine plus clomipramine) (Type: ACTIVE_COMPARATOR): Fluoxetine up to 40mg once a day plus clomipramine up to 75mg once a day, during 12 weeks
- Placebo (fluoxetine plus placebo) (Type: PLACEBO_COMPARATOR): Fluoxetine up to 80 mg once a day plus placebo 3 pills once a day, during 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).